44 Events after the balance sheet date

44 Events after the balance sheet date

There have been no events after the balance sheet date.

On 10 October 2019, UCB announced its entry into a merger agreement pursuant for which UCB will acquire Ra Pharmaceuticals Inc (NASDAQ: RARX, Ra Pharma). Under the terms of the agreement, Ra Pharma shareholders will receive USD 48 in cash for each Ra Pharma share at closing. This would bring the total transaction value to approximately USD 2.1 billion (net of Ra Pharma cash). The Boards of Directors of both companies have unanimously approved the transaction, which remains subject to approval by Ra Pharma shareholders and to obtaining antitrust clearance and other customary closing conditions. UCB and Ra Pharma expect to complete the transaction by the end of Q1 2020.